(Source: BioLineRX Ltd) - Data strongly suggest BL-8040 has potent anti-leukemic activity in combination with Ara-C in AML - - Results to be presented at 2015 ASH Annual Meeting - TEL AVIV, Israel--(BUSINESS WIRE)--Nov. 5, 2015-- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive results from the dose escalation part of BL-8040’s Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia (r/r AML). The results will be presented at the 57th American Society of Hematology (ASH) Annual Meeting, to be held December 5-8, 2015 in Orlando,...
↧